Samsung Biologics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Samsung Biologics is a fully integrated CDMO offering a mammalian cell line & process development to cGMP clinical & commercial manufacturing (DS/DP) and biosafety testing services, all from a single location. We provide highly tailored solutions to each client in need. Established in April 2011, Samsung Biologics' core business activities include Upstream & Downstream Process Development, Clinical & Commercial manufacturing, Aseptic Fill/Finish, and Analytical & Biosafety testing. With our manufacturing sites located in South Korea, all plants are cGMP compliant holding 364KL total capacity with flexible clinical & commercial scales of 1KL, 5KL, 15KL. With a dedicated Quality Control Lab & Process Development Unit and designed as multi-product facilities to meet the requirements of the US FDA, EMA, and other global regulatory agencies. Recently, 4KL of Single-use bioreactors have added, which provides us further flexibility to accommodate a wide range of clients' demands.
Ticker:
207940
Exchange:
KRX
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
conf.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Associate Director, DSP MSAT
Samsung Biologics